Sponsor

Tecnimede-Sociedade Tecnico-Medicinal S.A.

Portugal Rua Da Tapada Grande 2 Abrunheira, 2710-228, Portugal

About the sponsor

Tecnimede-Sociedade Tecnico-Medicinal S.A. has active clinical research in type 2 diabetes-related treatment areas, with work centered on empagliflozin, canagliflozin, and alogliptin formulations. This includes interest in SGLT2 inhibitors and DPP-4 inhibitors used in glycaemic management.

Empagliflozin
Canagliflozin
Alogliptin
SGLT2 inhibitor
DPP-4 inhibitor

The sponsor also investigates combination-related therapeutic areas involving glucose-lowering agents, reflecting a focus on oral treatments for metabolic disease.

About Specializations

Tecnimede-Sociedade Tecnico-Medicinal S.A. runs clinical trials in conditions such as Type 2 diabetes mellitus, among others.

Type 2 diabetes mellitus

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Quick filters

2 clinical trials

Type 2 diabetes mellitus

Not yet recruiting

Efficacy and Safety of Alogliptin Plus Empagliflozin Compared with Alogliptin Alone or Empagliflozin Alone in Adults with Type 2 Diabetes on Metformin

Registered drug